Materials and methods for inhibiting Wip1
AssigneeThe Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
InventorsDmitry Bulavin, Galina Belova, Albert J. Fornace
Life of this patent
Estimating the term…
Abstract
The invention provides a method of treating cancer in a mammal that expresses the same level or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, and a method of inhibiting Wip1 in a cell. The invention also provides pharmaceutical compositions comprising a compound selected from the group consisting of Compounds A-N, and a method of making a cancer therapeutic composition. Also provided is a compound selected from the group consisting of Compounds A-N, a method of screening a compound for Wip1-inhibiting activity, and a method of determining the efficacy with which a test compound inhibits Wip1.
Claims25
A method of treating cancer in a mammal that expresses the same level or a higher level of Wip1 as compared to a mammal of the same species that does not have cancer, which method comprises administering to the mammal a cancer-treating effective amount of a Wip1 inhibitor, whereupon the mammal is treated for cancer.
A method of inhibiting Wip1 phosphatase activity in a cell, which method comprises administering to the cell a compound selected from the group consisting of Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, Compound M, and Compound N, or a pharmaceutically-acceptable salt of any of the foregoing, in an amount effective for inhibiting Wip1 phosphatase activity in a cell.
A pharmaceutical composition comprising a compound selected from the group consisting of Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, Compound M, and Compound N, or a pharmaceutically-acceptable salt of any of the foregoing, and a pharmaceutically-acceptable carrier.
A method of making a cancer therapeutic composition, which method comprises formulating a compound selected from the group consisting of Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, Compound M, and Compound N, or a pharmaceutically-acceptable salt of any of the foregoing, with a pharmaceutically-acceptable carrier.
A compound selected from the group consisting of Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, Compound M, and Compound N, or a pharmaceutically-acceptable salt of any of the foregoing.
A method of screening a compound for Wip1-inhibiting activity, which method comprises comparing the level of Wip1 phosphatase activity in a test sample that has been contacted with the compound to the level of Wip1 phosphatase activity in a control sample that has not been contacted with the compound, wherein a lower level of Wip1 phosphatase activity in the test sample as compared to the control sample is indicative of the ability of the compound to inhibit Wip1.
A method of determining the efficacy with which a test compound inhibits Wip1, which method comprises comparing the level of Wip1 phosphatase activity in a test sample that has been contacted with the test compound to the level of Wip1 phosphatase activity in a control sample that has been contacted with a compound that is known to inhibit Wip1, wherein a lower level of Wip1 phosphatase activity in the test sample as compared to the control sample is indicative of the test compound having a greater efficacy for inhibiting Wip1 than the known compound and wherein a higher level of Wip1 phosphatase activity in the test sample as compared to the control sample is indicative of the test compound having a lower efficacy for inhibiting Wip1 than the known compound.
Dependencies are inferred from the claim text.